Show All
When was Genmab listed, what is the stock symbol and on which Stock Exchange is the company's stock traded?

Genmab became a publicly traded company in 2000. Genmab’s ordinary shares are listed on Nasdaq Copenhagen under the symbol GMAB, and it is a member of the OMX Nordic Large Cap Index, the OMX Copenhagen Benchmark Index and the OMX Copenhagen 25 Index (OMXC25). Genmab’s ID code/ISIN is DK0010272202. In July 2019, Genmab’s American Depositary Shares issued pursuant to its ADR program were also listed in the United States on the Nasdaq Global Select Market under the symbol GMAB and are part of the NASDAQ Biotechnology Index (Nasdaq: NBI).

How many shareholders does Genmab have? How many shares are outstanding?

Genmab has approximately 64,000 registered shareholders. There are 65,280,093 shares outstanding. Each share has a nominal value of DKK 1, resulting in a share capital of DKK 65,280,093.

Where is Genmab located?

Genmab is headquartered in Copenhagen, Denmark and its main research activities are in Utrecht, the Netherlands. Genmab has development and administrative teams in both Copenhagen, Denmark and Princeton, NJ, USA and a regional office in Japan. 

Does Genmab have any subsidiaries?

Genmab has four subsidiaries: Genmab B.V. and Genmab Holding B.V. in the Netherlands, Genmab US, Inc. in the United States and Genmab K.K. in Japan.

What is the number of employees of Genmab?

On March 31, 2020 Genmab had 579 full time employees.

What kind of products does Genmab develop?

Genmab develops antibody therapeutics. Genmab's main focus is on products that can be used to treat cancer. To read more about the company's products in clinical development please go to the Products in development page. 

How many products does Genmab have on the market?

There are three Genmab-created products that have received regulatory approval: DARZALEX® (daratumumab), Arzerra® (ofatumumab) and TEPEZZA™ (teprotumumab-trbw). Read more about these products on our Products in development page.

Does Genmab have other products in development?

Yes, Genmab has a number of products in clinical and pre-clinical development. Refer to our product pipeline for more information.

Where can I find financial information on sales and earnings?

You can find our interim financial reports and annual reports in the Financial reports section of this website.

How does Genmab create antibodies?
  • Our proprietary DuoBody® technology platform enables us to create human bispecific antibodies that bind to two different targets.
  • Genmab’s novel proprietary HexaBody® platform is designed to increase the potency of antibodies. The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases.
  • Antibody Drug Conjugate (ADC) technology, licensed from other companies, combines antibodies with cytotoxic agents to selectively target tumor cells.
  • Antibody generation technology platforms such as the OmniAb® transgenic mouse and rat platforms and the UltiMAb® transgenic mouse technology are used to create antibodies.

For more information on how Genmab creates antibodies and how these technologies work, visit the Introduction to antibodies and Genmab technology pages of this website.

Where can I read more about Genmab's position on Corporate Governance and CSR?

More information about our Corporate Governance and CSR policies and initiatives can be found on the Corporate governance and CSR sections of this website.

Who are Genmab's auditors?

PricewaterhouseCoopers is Genmab's auditor.

Who should I contact regarding shareholder and investor relations questions?

For Media and Investor Relations please contact:  
Marisol Peron
Corporate Vice President, Communications & Investor Relations
Telephone: +1 609 524 0065
Email: mmp@genmab.com 

For Investor Relations please contact:
Andrew Carlsen
Senior Director, Investor Relations
Telephone: +45 3377 9558
Email: acn@genmab.com

Does Genmab have an ADR program?

Yes, Genmab has established a sponsored Level 3 ADR program. American Depositary Shares issued under the ADR Program are listed on the Nasdaq Global Select Market in the United States under the symbol GMAB. Click here for more information.